The Top 50 Pharmaceutical Companies mentioned by eHCPs on X
September Rank | August Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
---|---|---|---|---|---|
1 | 1 | Pfizer | 2,371 | 205 | 7 |
2 | 2 | Moderna | 1,609 | 50 | 9 |
3 | 9 | Novavax | 1,604 | 176 | 25 |
4 | 5 | Johnson & Johnson | 639 | 75 | 1 |
5 | 4 | GSK | 535 | 123 | 16 |
6 | 7 | AstraZeneca | 472 | 260 | 10 |
7 | 11 | Novo Nordisk | 423 | 211 | 29 |
8 | 8 | Roche | 328 | 140 | 9 |
9 | 10 | Bayer | 308 | 70 | 5 |
10 | 3 | Gilead Sciences | 241 | 78 | 5 |
11 | 13 | Merck & Co | 239 | 74 | 7 |
12 | 12 | Sanofi | 221 | 89 | 15 |
13 | 14 | Abbott | 220 | 201 | 22 |
14 | 6 | Lilly | 155 | 86 | 1 |
15 | 19 | Boehringer Ingelheim | 131 | 99 | 20 |
16 | 18 | AbbVie | 121 | 88 | 20 |
17 | 17 | Novartis | 111 | 66 | 0 |
18 | 16 | Otsuka | 98 | 7 | 0 |
19 | 29 | BMS | 91 | 40 | 6 |
20 | 25 | Amgen | 89 | 67 | 3 |
21 | 15 | Fresenius | 86 | 56 | 6 |
22 | 27 | Regeneron | 62 | 34 | 1 |
23 | 26 | Chugai | 60 | 2 | 2 |
24 | 28 | Takeda | 60 | 57 | 0 |
25 | 39 | Astellas | 59 | 33 | 0 |
26 | 23 | Organon | 50 | 7 | 0 |
26 | 42 | Dr. Reddy's Labratories | 50 | 27 | 0 |
28 | 20 | Daiichi Sankyo | 47 | 26 | 4 |
28 | 37 | UCB | 47 | 18 | 4 |
30 | 22 | Biogen | 41 | 9 | 0 |
31 | 30 | STADA Arneimittel | 37 | 4 | 0 |
32 | 33 | Vertex | 28 | 27 | 0 |
33 | 21 | Teva | 24 | 19 | 1 |
33 | 24 | Eisai | 24 | 6 | 0 |
33 | 31 | Merck KGaA | 24 | 20 | 7 |
36 | 33 | Servier | 22 | 7 | 0 |
37 | 35 | Ipsen | 16 | 10 | 2 |
38 | 36 | Sun | 12 | 1 | 0 |
39 | 39 | CSL | 10 | 7 | 0 |
40 | 32 | Bausch | 8 | 4 | 1 |
40 | 41 | Viatris | 8 | 0 | 0 |
42 | 43 | Menarini | 7 | 1 | 1 |
43 | 44 | Incyte | 6 | 5 | 0 |
44 | 38 | Jazz Pharmaceuticals | 3 | 1 | 0 |
45 | 44 | Grifols | 2 | 0 | 0 |
46 | 50 | Jiangsu Hengrui | 1 | 0 | 0 |
50 | 50 | Shanghai | 0 | 0 | 0 |
50 | 50 | Sino | 0 | 0 | 0 |
50 | 50 | Yunnan Baiyao Group | 0 | 0 | 0 |
50 | 50 | Mitsubishi Chemical Group | 0 | 0 | 0 |
September’s insights from eHCPs mentioning the Top 50 Pharmaceutical Companies
The five most mentioned pharmaceutical companies by eHCPs on X in September 2024 were Pfizer, Moderna, Novavax, Johnson & Johnson and GSK.
CREATION.co identified 9,541 eHCP mentions of pharmaceutical companies in September 2024, an increase of 21.4% compared to the previous month.
On 04 September, eHCPs went on X to discuss the Novavax vaccine. The discussion came from a Novavax post – stating that their data indicated that the Novavax vaccine protects against the main circulating variants of the virus. One commenter described this update as “good news for Novavax fans”, which was shared by 2 eHCPs.
Good news for Novavax fans 😊
👏👏👏 https://t.co/MxVg8ijW5m— Barry Hunt ————————– Novavax 4 Me (@BarryHunt008) September 4, 2024
Shared by 2 eHCPs
On 23 September, the eHCP conversation around the Novavax vaccine picked up again. This time, eHCPs discussed the availability of the vaccine in Canada, where patients are struggling to get access to it. eHCPs shared an update that vaccine access is likely to be coming over the next month.
🇨🇦 Novavax Availability Update 📢
Durham Region Public Health Unit is reportedly saying that they're expecting to have Novavax access sometime in October.
This suggests that Ontario may be working behind the scenes on procuring Novavax for PHUs.
Has anyone else heard more? https://t.co/tt1gcYhrZP
— Friesein (@Friesein) September 23, 2024
Shared by 98 eHCPs
The update for vaccine availability resonated strongly with eHCPs as 98 of them reshared this post. Public and eHCP calls for governing bodies to procure these vaccines was largely supported.
Dear @PublicHealthON,
I want @Novavax
Thanks
(Pass it on)@TOPublicHealth https://t.co/6qIrhFCTZh
— Jennifer Baer (@thejenniferbaer) September 23, 2024
Nutritionist. 2 other eHCPs also shared a post with the same content.
On 26 September, eHCPs discussed the REGENCY trial by Roche, which evaluated obinutuzumab for the treatment of lupus nephritis. Nephrologist Juan Manuel Mejía shared the press release and applauded the results.
Roche announces the REGENCY trial studying obinutuzumab for #lupusnephritis met its primary efficacy endpoint… New options for the management of lupus and lupus nephritis 👏https://t.co/EkKrMWPDWH pic.twitter.com/weVX5fwvnc
— Juan Manuel Mejía (@Meyaix) September 26, 2024
Shared by 5 eHCPs
The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:
- A Gilead press release for trial results for Lenacapavir for the prevention of HIV.
- An academic journal describing the association between SARS-CoV-2 viral load and COVID-19 vaccinations.
- A news report of Moderna’s mpox vaccine showing promising results.
——
Find out how the conversation is changing in other Top 50 Trackers and new analysis of the online HCP conversation in a variety of topics.
You can also receive these updates and more straight to your inbox by signing up to CREATION.co’s monthly eJournal.
Methodology notes:
- In September 2024, CREATION Pinpoint® identified 9,541 posts on X (Twitter) from 4,268 individual eHCPs mentioning a Top 50 Pharmaceutical company (based on revenue).
- Data for this research was analysed from the online X conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 – 30 September 2024.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, a post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In September 2024, 68 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.